Info

Cytran, Inc. is a privately held biopharmaceutical company, developing and commercializing drugs that fight cancer through stimulating immune system response and inhibiting angiogenesis. In addition to ovarian cancer, IM862 is currently being evaluated for use in treating patients with AIDS-associated Kaposi's sarcoma, prostate, breast and colorectal cancers.